# Combining Epigenetic And Immune Therapy to Beat Cancer.

> **NCT04705818** · PHASE2 · COMPLETED · sponsor: **Institut Bergonié** · enrollment: 164 (actual)

## Conditions studied

- Advanced Solid Tumor
- Advanced Colorectal Carcinoma
- Advanced Soft-tissue Sarcoma
- Advanced Pancreatic Adenocarcinoma
- Adult Solid Tumor

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Tazemetostat

## Key facts

- **NCT ID:** NCT04705818
- **Lead sponsor:** Institut Bergonié
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-23
- **Primary completion:** 2024-01-07
- **Final completion:** 2025-07-17
- **Target enrollment:** 164 (ACTUAL)
- **Last updated:** 2026-03-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04705818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04705818, "Combining Epigenetic And Immune Therapy to Beat Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04705818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*